Literature DB >> 25550960

Association between polymorphisms in the integrin gene predicted microRNA binding sites and bladder cancer risk.

Jiaming Liu1, Sihang Cheng1, Yonggang Zhang2, Hong Li1, Jin Huang3, Peng Zhang1.   

Abstract

Bladder cancer (BC) is the ninth most frequent malignancies in the world and the occurrence of this disease has dramatically increased in recent years. Integrins have been demonstrated to play an important role in the development and progression of BC. However, the association between polymorphisms in integrin genes and BC susceptibility was still unclear. A number of studies mainly focused on polymorphisms in the coding regions of integrin genes previously, while in this study, polymorphisms in the 3' untranslated regions (3'UTR) were investigated in Chinese Han population. According to previous study, seven single-nucleotide polymorphisms (SNPs) in predicted microRNA (miRNA) target sites were chosen as potential targets. And four SNPs including rs11902171, rs2675, rs17664, and rs1062484, were finally examined for their effect on BC risk and clinical prognosis. These four polymorphisms were genotyped by using the high-resolution melting method (HRM) in 317 BC patients with long-time follow-up together with 317 age-matched healthy controls. AC carriers of rs2675 in ITGB5 were associated with an increased risk of BC (OR 1.44, 95% CI 1.02-2.03). No significant relationship was detected between these SNPs and the recurrence-free survival time of overall study population or non-muscle invasive BC subgroups in univariable analysis. In conclusion, rs2675 in miRNA binding sites of ITGB5 might be a potential target for BC susceptibility prediction.

Entities:  

Keywords:  Integrin gene; bladder cancer; microRNA-binding sites; polymorphisms

Year:  2014        PMID: 25550960      PMCID: PMC4276218     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  42 in total

1.  Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin.

Authors:  S C Even-Ram; M Maoz; E Pokroy; R Reich; B Z Katz; P Gutwein; P Altevogt; R Bar-Shavit
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

Review 2.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

3.  Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A.

Authors:  Anna Desch; Elwira A Strozyk; Alexander T Bauer; Volker Huck; Verena Niemeyer; Thomas Wieland; Stefan W Schneider
Journal:  Am J Pathol       Date:  2012-05-31       Impact factor: 4.307

Review 4.  Alterations in antigen expression in superficial bladder cancer.

Authors:  H B Grossman; R W Washington; T E Carey; M Liebert
Journal:  J Cell Biochem Suppl       Date:  1992

5.  Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer.

Authors:  Debora Landi; Federica Gemignani; Alessio Naccarati; Barbara Pardini; Pavel Vodicka; Ludmila Vodickova; Jan Novotny; Asta Försti; Kari Hemminki; Federico Canzian; Stefano Landi
Journal:  Carcinogenesis       Date:  2008-01-12       Impact factor: 4.944

6.  Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.

Authors:  Annika Brendle; Haixin Lei; Andreas Brandt; Robert Johansson; Kerstin Enquist; Roger Henriksson; Kari Hemminki; Per Lenner; Asta Försti
Journal:  Carcinogenesis       Date:  2008-06-10       Impact factor: 4.944

7.  A miRNA binding site single-nucleotide polymorphism in the 3'-UTR region of the IL23R gene is associated with breast cancer.

Authors:  Lihong Wang; Wei Liu; Wei Jiang; Jing Lin; Yongdong Jiang; Bo Li; Da Pang
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

8.  Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways.

Authors:  A Bianchi-Smiraglia; S Paesante; A V Bakin
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

9.  Distribution of the cell substratum attachment (CSAT) antigen on myogenic and fibroblastic cells in culture.

Authors:  C H Damsky; K A Knudsen; D Bradley; C A Buck; A F Horwitz
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

10.  Platelet-derived growth factor receptor beta: a novel urinary biomarker for recurrence of non-muscle-invasive bladder cancer.

Authors:  Jiayu Feng; Weifeng He; Yajun Song; Ying Wang; Richard J Simpson; Xiaorong Zhang; Gaoxing Luo; Jun Wu; Chibing Huang
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more
  3 in total

1.  MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27.

Authors:  Chongjun Zhong; Shengguang Ding; Yiming Xu; Haitao Huang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder.

Authors:  Zhen Li; Kang-Er Wang; Xie-Lai Zhou; Jin Zhou; Chun-Hua Ye
Journal:  Med Sci Monit       Date:  2018-01-23

Review 3.  Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure.

Authors:  Fan Dong; Tianyuan Xu; Yifan Shen; Shan Zhong; Shanwen Chen; Qiang Ding; Zhoujun Shen
Journal:  Oncotarget       Date:  2017-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.